Written firmly from the perspective of the pharmaceutical industry, Laura Brown and Tony Grundy offer a guide to the tools and techniques of project management. They cover both the technical and human aspects of project management to provide clinical research, drug development and quality assurance managers or directors with a must-have reference.
This is the first book in the series of three. These three books will be based upon the idea to tailor PMI’s Project Management methodologies to the typical pharmaceutical projects.
This book will be beneficial for beginners to understand the concepts of project management and for small pharmaceutical companies to apply the principles of project management to their business model.
This book describes the way that pharmaceutical projects and programs are currently managed, and offers views from many highly experienced practitioners from within the industry on future directions for drug program management.
This book provides a practical reference for project managers in the pharmaceutical and biotech drug development industry, with the goal of assisting in creating an efficient and effective team structure and environment.
Project Management for the Pharmaceutical Industry
Chapter-by-chapter, the book addresses the following topics: Project leadership in the biomedical industry The role of project management throughout the product lifecycle Clinical trials and project management Project management in drug and ...
This book covers program management and how it relates to the healthcare industry and some of the project processes used by those companies involved in pharmaceuticals and manufacturers of medical devices.
Encompassing the full spectrum of project management’s role and responsibility encountered in the pharmaceutical industry, Pharmaceutical Project Management outlines the key objectives, risks, and challenges of each stage of the ...
Drawing on the experience of project managers from international pharmaceutical companies, this work reviews up-to-date strategic, operational and organizational procedures for drug development in today's competitive industry.
The contributions in this book by leading figures in industry, government, NGOs, the medical community, and academia discuss and propose solutions to the ethical dilemmas of drug industry behavior.